Verrica Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Verrica Pharmaceuticals

07/03/2025 13:34

Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to show a fall in quarterly revenue when it reports  results on March 11 for the period ending December 31 2024

The West Chester Pennsylvania-based  company is expected to report a 47.6% decrease in revenue to $1.041 million from $1.99 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Verrica Pharmaceuticals Inc is for a loss of 26 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $4.00​, above​ its last closing price of $0.62. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.39
-0.37
-0.49
Missed
-33.5
Jun. 30 2024
-0.43
-0.42
-0.37
Beat
12.9
Mar. 31 2024
-0.46
-0.40
-0.44
Missed
-10.9​
Dec. 31 2023
-0.53
-0.53
-0.53
Met
-0.4
​​Sep. 30 2023
-0.35
-0.36
-0.54
Missed
-49.5
Jun. 30 2023
-0.22
-0.21
-0.24
Missed
-14.2​
Mar. 31 2023
-0.18
-0.19
-0.15
Beat
21.1
Dec. 31 2022
-0.19
-0.19
-0.14
Beat
27.3

This summary was machine generated March 7 at 13:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)